Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07074327 · ClinicalTrials.gov registry record · Phase 1
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
A Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT07074327: Active Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.
NCT07074327 is a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 74 participants, below the 777-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07074327, a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.
Conditions Studied
Interventions
- DRUG VX-407
- DRUG LNG/EE
- DRUG NGM/EE
- DRUG NET/EE
- DRUG DRSP/EE
Study Locations (1)
Kansas
- Altasciences - Kansas City - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2025-07-11 |
| Est. Completion | 2026-07-04 |
| Phase | Phase 1 |
What the registry record for NCT07074327 still lists
NCT07074327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 777-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 5 interventions - of which VX-407 is the first listed.
NCT07074327 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT07074327 about?
NCT07074327 is a clinical study titled "Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants". The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 ...
What is the current status of trial NCT07074327?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2025-07-11. Estimated completion is 2026-07-04.
What conditions does trial NCT07074327 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).
What interventions are being tested in trial NCT07074327?
The interventions under investigation include: VX-407 (DRUG), LNG/EE (DRUG), NGM/EE (DRUG), NET/EE (DRUG), DRSP/EE (DRUG).
Who is sponsoring clinical trial NCT07074327?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07074327 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
RECRUITING · NA
-
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
RECRUITING · Phase 2
-
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
ACTIVE NOT RECRUITING
-
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI